Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Feb 05, 2020 |
print number 7196a |
Feb 05, 2020 |
amend (t) and recommit to consumer affairs and protection |
Jan 08, 2020 |
referred to consumer affairs and protection |
Apr 12, 2019 |
referred to consumer affairs and protection |
Assembly Bill A7196
2019-2020 Legislative Session
Sponsored By
DENDEKKER
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Bill Amendments
co-Sponsors
Walter T. Mosley
Jonathan Jacobson
William Colton
Marianne Buttenschon
2019-A7196 - Details
2019-A7196 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ S. 5169 A. 7196 2019-2020 Regular Sessions S E N A T E - A S S E M B L Y April 12, 2019 ___________ IN SENATE -- Introduced by Sen. BIAGGI -- read twice and ordered print- ed, and when printed to be committed to the Committee on Consumer Protection IN ASSEMBLY -- Introduced by M. of A. DenDEKKER -- read once and referred to the Committee on Consumer Affairs and Protection AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. This act shall be known and may be cited as the "manufac- turer disclosure and transparency act". § 2. The general business law is amended by adding a new section 396- rrr to read as follows: § 396-RRR. DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1. (A) EACH PHARMACEUTICAL MANUFACTURER DOING BUSINESS IN THIS STATE THAT MANUFAC- TURES A BRAND NAME PRESCRIPTION DRUG AND ENTERS INTO AN AGREEMENT WITH ANOTHER PHARMACEUTICAL MANUFACTURER FOR THE PURPOSE OF DELAYING OR PREVENTING SUCH OTHER MANUFACTURER FROM INTRODUCING A GENERIC SUBSTITUTE FOR SUCH DRUG INTO THE MARKETPLACE SHALL, NOT LATER THAN THIRTY DAYS AFTER ENTERING INTO SUCH AGREEMENT, SEND NOTICE TO THE ATTORNEY GENERAL, IN A FORM AND MANNER PRESCRIBED BY THE ATTORNEY GENERAL, DISCLOSING THE NAME OF SUCH DRUG, THE WHOLESALE PRICE, THE DISEASE SUCH DRUG IS COMMON- LY PRESCRIBED TO TREAT, THE MANUFACTURER OF SUCH DRUG, THE NAME OF THE GENERIC MANUFACTURER, AND THE LENGTH OF THE DELAY. (B) THE ATTORNEY GENERAL SHALL, NO LATER THAN THIRTY DAYS AFTER RECEIVING A NOTICE PURSUANT TO PARAGRAPH (A) OF THIS SUBDIVISION, SHARE THE INFORMATION WITH THE DRUG UTILIZATION REVIEW BOARD ESTABLISHED UNDER SECTION THREE HUNDRED SIXTY-NINE-BB OF THE SOCIAL SERVICES LAW, ALL EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
co-Sponsors
Walter T. Mosley
Jonathan Jacobson
William Colton
Marianne Buttenschon
2019-A7196A (ACTIVE) - Details
2019-A7196A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ S. 5169--A A. 7196--A 2019-2020 Regular Sessions S E N A T E - A S S E M B L Y April 12, 2019 ___________ IN SENATE -- Introduced by Sens. BIAGGI, BENJAMIN, CARLUCCI, GAUGHRAN, HOYLMAN, JACKSON, MAY, MYRIE, PARKER, SALAZAR -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection -- recommitted to the Committee on Consumer Protection in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee IN ASSEMBLY -- Introduced by M. of A. DenDEKKER, MOSLEY, JACOBSON, COLTON, BUTTENSCHON, HEVESI, STIRPE, REYES, BARRON, PICHARDO, SEAWRIGHT, CARROLL, LENTOL, LiPETRI, ASHBY, WEPRIN, SIMON, LIFTON, BENEDETTO, D'URSO, HUNTER, MONTESANO, GOTTFRIED, CRUZ -- read once and referred to the Committee on Consumer Affairs and Protection -- recom- mitted to the Committee on Consumer Affairs and Protection in accord- ance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said commit- tee AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. This act shall be known and may be cited as the "manufac- turer disclosure and transparency act". § 2. The general business law is amended by adding a new section 396- rrr to read as follows: § 396-RRR. DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1. (A) EACH PHARMACEUTICAL MANUFACTURER DOING BUSINESS IN THIS STATE THAT MANUFAC- TURES A BRAND NAME PRESCRIPTION DRUG AND ENTERS INTO AN ARRANGEMENT, THROUGH AGREEMENT OR OTHERWISE, WITH ANOTHER PHARMACEUTICAL MANUFACTURER EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.